Mubasher: Moderna Inc on Monday said its experimental vaccine was 94.5% effective in preventing COVID-19 based on interim data from a late-stage trial, becoming the second US drugmaker to report results that far surpass expectations, Reuters reported.
Together with Pfizer Inc’s vaccine, which is also more than 90% effective, the US could have two vaccines authorised for emergency use in December with as many as 60 million doses of vaccine available this year.
Next year, the US government could have access to more than 1 billion doses just from the two vaccine makers, which is more than needed for the country’s 330 million residents.
“We are going to have a vaccine that can stop COVID-19,” Moderna President, Stephen Hoge, told Reuters.
Moderna expects to have enough safety data required for US authorisation in the next week and predicts to file for emergency use authorisation (EUA) over the coming weeks.